Neuropathy Treatment for Feet 2026 | Podiatrist

Treatment	Evidence Level	Pain Reduction	Best For	Notes
Blood glucose optimization (HbA1c <7%)	Level I	Slows progression; partial reversal early	Diabetic neuropathy — fundamental	Most important single intervention
Duloxetine (Cymbalta) 60–120mg/day	Level I	30–50% reduction	Diabetic peripheral neuropathy	FDA-approved; also treats depression
Pregabalin (Lyrica) 150–600mg/day	Level I	30–50% reduction	Diabetic + post-herpetic neuropathy	FDA-approved; sedation common side effect
Gabapentin 1800–3600mg/day	Level I	30–45% reduction	All neuropathic pain types	Off-label for DPN; lower cost than pregabalin
Topical capsaicin 8% patch	Level I	30–40% reduction (3 months)	Localized burning/shooting pain	Applied in-office; painful application
MLS laser (class IV, 635+905nm)	Level II	40–60% in clinical series	DPN; drug-free option for drug-intolerant	6–10 session series; no side effects
Tricyclic antidepressants (amitriptyline)	Level I	30–40% (less than duloxetine)	Second-line; low cost	Anticholinergic side effects; use low dose
Alpha-lipoic acid 600mg/day	Level II	Modest improvement	Supplement adjunct; antioxidant	Intravenous ALA has stronger evidence than oral

Neuropathy Type	Most Common Cause	Reversible?	Key First Step
Diabetic peripheral neuropathy (DPN)	Hyperglycemia-induced nerve damage	Partial (early); halt progression	Optimize HbA1c; podiatry follow-up
Vitamin B12 deficiency neuropathy	Metformin use, vegan diet, pernicious anemia	Often highly reversible	B12 supplementation / injections
Alcoholic neuropathy	Ethanol neurotoxicity + B vitamin deficiency	Partially reversible with abstinence	Cessation + thiamine/B12 supplementation
Chemotherapy-induced neuropathy (CIPN)	Taxanes, platinum agents, vincristine	Variable (months–years)	Duloxetine; balance PT; supportive care
Idiopathic small fiber neuropathy	Unknown (10–25% all neuropathy)	Stabilizes in most; some improve	Skin biopsy for diagnosis; lifestyle optimization
Tarsal tunnel syndrome	Nerve compression (not systemic)	Yes — with decompression	Orthotics; surgical release if severe

Quick answer: Treatment for neuropathy treatment feet follows a stepwise approach: 1) conservative care first (rest, ice, supportive footwear, OTC anti-inflammatories), 2) physical therapy and targeted exercises, 3) in-office treatments (injections, custom orthotics) if conservative fails at 4-6 weeks, 4) surgery for refractory cases. Most patients resolve at step 1 or 2. Call (810) 206-1402.

Peripheral neuropathy affecting the feet is one of the most common and most impactful conditions we manage. It affects approximately 20 million Americans — most commonly from diabetes, but also from dozens of other causes. The tragedy is that many patients suffer for years without a clear diagnosis or effective treatment plan.

The good news: treatment has advanced significantly. We now have effective medications for pain, better understanding of the underlying mechanisms, and evidence-based approaches for slowing progression and preventing the devastating complications — like foot ulcers and amputations — that make neuropathy truly dangerous.

Types of Foot Neuropathy and Their Causes

Neuropathy is not one disease — it’s a symptom of nerve damage from many different causes. Understanding which type you have determines which treatments will be effective:

Diabetic Peripheral Neuropathy (DPN)

The most common type, affecting 50–70% of people with long-standing diabetes. High blood glucose damages the small blood vessels that supply nerves (vasa nervorum) and directly injures nerve fibers through glycation (sugar binding to proteins). Symptoms are bilateral, symmetric, stocking-glove distribution — starting in the toes and moving upward. Both painful (burning, electric) and painless (loss of sensation) types occur.

B12 Deficiency Neuropathy

Vitamin B12 is essential for myelin synthesis — the insulating sheath around nerves. Deficiency causes progressive demyelination starting at the feet. At highest risk: older adults, strict vegans, long-term metformin users, people with pernicious anemia, and anyone with prior gastric surgery. Often reverses significantly with treatment if caught early.

Idiopathic Small Fiber Neuropathy

Affects only the smallest nerve fibers (pain and temperature fibers) — the ones that don’t show up on standard nerve conduction studies. Causes intense burning, often worse at night, with normal NCS/EMG. Diagnosed by skin punch biopsy. Associated with diabetes, autoimmune disease, and genetic variants. Up to 30% have no identifiable cause.

Chemotherapy-Induced Peripheral Neuropathy (CIPN)

Certain chemotherapy agents — particularly platinum-based drugs (oxaliplatin, cisplatin) and taxanes (paclitaxel, docetaxel) — cause significant peripheral neuropathy. CIPN affects approximately 30–40% of chemotherapy patients and is dose-dependent. May be temporary or permanent. Duloxetine is the only medication with demonstrated efficacy for CIPN pain.

Alcohol-Related Neuropathy

Chronic alcohol use causes neuropathy through direct neurotoxicity and associated thiamine (B1) and B12 deficiency. Presents similarly to diabetic neuropathy. Partial reversal is possible with abstinence and nutritional supplementation.

• Other causes: hypothyroidism, kidney disease, HIV, Lyme disease, lupus, rheumatoid arthritis, hereditary neuropathies (Charcot-Marie-Tooth), amyloidosis, monoclonal gammopathy

Diagnosing Neuropathy: What Tests We Order

Evaluation of foot neuropathy includes:

• History: symptom quality, distribution, progression, associated conditions, medications, alcohol use, family history
• Physical examination: monofilament sensation (10g Semmes-Weinstein), vibration perception (128 Hz tuning fork), temperature sensation, reflex testing, strength assessment
• Lab work: fasting glucose, HbA1c, B12 (methylmalonic acid if borderline), complete metabolic panel, TSH, CBC, serum protein electrophoresis (SPEP)
• Nerve conduction study/EMG: large fiber neuropathy assessment — quantifies severity and distribution
• Skin punch biopsy: intraepidermal nerve fiber density — gold standard for small fiber neuropathy
• Quantitative sensory testing: detailed threshold measurement for heat, cold, vibration

Treatment: A Layer-by-Layer Approach

Effective neuropathy treatment works on multiple levels simultaneously: address the underlying cause, manage pain symptoms, prevent complications, and protect the at-risk foot.

Layer 1: Treat the Underlying Cause

• Diabetic neuropathy: achieve and maintain HbA1c < 7% — every 1% reduction slows neuropathy progression by ~30%
• B12 deficiency: oral methylcobalamin 1,000–2,000 mcg/day or monthly injectable cyanocobalamin
• Thyroid disease: appropriate thyroid hormone replacement
• Alcohol neuropathy: abstinence + thiamine 100 mg/day + B-complex
• CIPN: dose modification with oncologist if possible; duloxetine for pain

Layer 2: Manage Neuropathic Pain

Gabapentin (300–3600 mg/day in divided doses) and pregabalin (75–300 mg/day) are calcium channel alpha-2-delta ligands — first-line for diabetic and other peripheral neuropathic pain. They reduce abnormal nerve firing. Common side effects: sedation, dizziness, weight gain.

Duloxetine (60–120 mg/day) is the only SNRI FDA-approved for diabetic peripheral neuropathy. Also effective for CIPN. Works by inhibiting serotonin and norepinephrine reuptake in the descending pain inhibitory pathways.

Tricyclic antidepressants (amitriptyline 25–75 mg at bedtime) are effective for neuropathic pain but have significant anticholinergic side effects — use cautiously in older adults.

Topical treatments: lidocaine 5% patches (Lidoderm) effective for localized areas; capsaicin 8% patch (Qutenza) for peripheral neuropathy with strong evidence; topical diclofenac for focal pain.

Layer 3: Supplements with Evidence

• Alpha-lipoic acid 600 mg/day — reduces oxidative stress; multiple RCTs show symptom reduction in DPN; well tolerated
• Methylcobalamin (B12) — essential if deficient; some evidence for benefit even in non-deficient neuropathy
• Benfotiamine (fat-soluble B1) — reduces advanced glycation end-products; evidence in DPN
• Acetyl-L-carnitine — may improve nerve regeneration; evidence for CIPN and DPN
• Vitamin D — deficiency associated with worse neuropathy; correct to 40–60 ng/mL

Layer 4: Foot Protection and Podiatric Care

Loss of protective sensation (inability to feel a 10g monofilament) is the critical threshold that makes neuropathic feet vulnerable to ulcers and amputations. Once protective sensation is lost, the foot must be actively managed:

• Daily foot inspection — every single day; use a mirror for the sole
• Diabetic/therapeutic footwear — depth shoes with cushioned insoles, Medicare-covered with DM diagnosis
• Never walk barefoot on any surface
• Professionally fitted socks — seamless, moisture-wicking, non-constricting
• Podiatric visits every 3 months for nail care, callus management, ulcer surveillance
• Custom orthotics to redistribute pressure and prevent callus formation over bony prominences

Emerging Treatments on the Horizon

Research in neuropathy treatment is active. Promising areas include: corneal confocal microscopy (non-invasive early detection of nerve fiber loss), stem cell therapy for nerve regeneration, gene therapy targeting the TRPV1 pain channel, and improved forms of spinal cord stimulation for refractory neuropathic pain. Several clinical trials are underway for novel agents targeting the mechanisms of glycation-induced nerve damage.

Frequently Asked Questions: Neuropathy Treatment for Feet

Can neuropathy in the feet be reversed?

Whether neuropathy is reversible depends on the cause and duration. B12 deficiency neuropathy is often substantially reversible with supplementation. Diabetic neuropathy can stabilize and partially improve with excellent glucose control, especially if caught early. Long-standing neuropathy with significant nerve fiber loss has limited reversal potential but symptoms can be effectively managed. Early treatment consistently produces better outcomes than late treatment.

What is the best medication for neuropathy pain in the feet?

No single medication is best for everyone. Gabapentin and pregabalin are the most widely used first-line options. Duloxetine is preferred when depression or anxiety co-exists, and is FDA-approved specifically for diabetic neuropathy. Many patients require combination therapy — medication plus topical treatment plus supplements. Work with your provider to find the right combination for your specific type and severity.

Does walking help or hurt neuropathy?

Regular moderate-intensity walking (30 minutes, 5 days per week) has demonstrated benefits for diabetic peripheral neuropathy: improved nerve conduction velocity, reduced pain scores, and better glycemic control. The key is appropriate protective footwear and daily foot inspection. Walking on a treadmill allows controlled surface and speed. Balance exercises are especially important as proprioception is often affected.

Can diet help neuropathy?

Yes — particularly for diabetic and inflammatory neuropathy. An anti-inflammatory diet (Mediterranean pattern: rich in vegetables, whole grains, fish, olive oil; low in processed foods, refined sugar, alcohol) reduces the systemic inflammation that worsens nerve damage. Adequate protein for myelin repair, foods rich in B vitamins, and controlled carbohydrate intake are specific priorities.

Why is neuropathy worse at night?

Several factors converge at night: the distraction of daytime activity disappears (making pain more prominent), body temperature and blood flow to the skin change, and cortisol levels drop (removing natural anti-inflammatory suppression). Lying flat can alter blood flow patterns in the feet. Medications like gabapentin taken at bedtime are partially effective because they target the aberrant nerve firing that peaks during these quieter periods.

Sources

• Pop-Busui R, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136–154.
• Callaghan BC, et al. Enhanced Glucose Control for Preventing and Treating Diabetic Neuropathy. Cochrane Database Syst Rev. 2012;6:CD007543.
• Stein C, et al. Alpha-Lipoic Acid for Diabetic Peripheral Neuropathy: A Systematic Review. J Diabetes Complications. 2024;38(4):108723.
• Griebeler ML, et al. Pharmacologic Interventions for Painful Diabetic Neuropathy: An Umbrella Systematic Review and Comparative Effectiveness Network Meta-Analysis. Ann Intern Med. 2014;161(9):639–649.
• Ziegler D, et al. Treatment of Symptomatic Diabetic Peripheral Neuropathy with the Antioxidant Alpha-Lipoic Acid. Diabetologia. 1995;38(12):1425–1433.

American Podiatric Medical Association: Neuropathy